<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04544722</url>
  </required_header>
  <id_info>
    <org_study_id>Jianfei Kangfu Cao</org_study_id>
    <nct_id>NCT04544722</nct_id>
  </id_info>
  <brief_title>Clinical Study of Jianfei Kangfu Cao in the Treatment of pSS-ILD</brief_title>
  <official_title>Clinical Study of Jianfei Kangfu Cao in the Treatment of Primary Sjogren's Syndrome Associated Interstitial Lung Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of Jianfei Kangfu Cao in the treatment of&#xD;
      primary Sjogren's syndrome associated interstitial lung disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomized, double-blind, positive control clinical trial with a course&#xD;
      of 24 weeks.&#xD;
&#xD;
        1. Random scheme:the DAS for Interactive Web Response System(IWRS) will be used to&#xD;
           calculate and distribute random numbers and dispensing drugs.&#xD;
&#xD;
        2. Blind method ：The test process will be in a double-blind state.&#xD;
&#xD;
        3. Control drug: The lung rehabilitation training will be used as control in this trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FVC</measure>
    <time_frame>24 weeks</time_frame>
    <description>FVC is an index of lung function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CAT score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cat questionnaire includes eight questions, the core of which is cough, expectoration, chest tightness, sleep, energy, emotion, and two tolerance evaluation indexes, namely, exercise endurance and daily exercise influence. According to the patient's own situation, each item was scored accordingly (0-5), and the cat score range was 0-40</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6MWD</measure>
    <time_frame>24 weeks</time_frame>
    <description>Six minutes walk test is a kind of exercise test for the functional state of patients with moderate and severe cardiopulmonary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESSDAI</measure>
    <time_frame>24 weeks</time_frame>
    <description>Evaluation of Sjogren's disease activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESSPRI</measure>
    <time_frame>24 weeks</time_frame>
    <description>EULAR SS Patient Reported Index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Primary Sjogren's Syndrome</condition>
  <condition>Interstitial Lung Disease</condition>
  <arm_group>
    <arm_group_label>Jianfei Kangfu Cao</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lung rehabilitation training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Jianfei Kangfu Cao</intervention_name>
    <description>The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.</description>
    <arm_group_label>Jianfei Kangfu Cao</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>lung rehabilitation training</intervention_name>
    <description>The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.</description>
    <arm_group_label>Lung rehabilitation training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. According to the 2012 ACR classification of primary Sjogren's syndrome .&#xD;
&#xD;
          2. CT confirmed interstitial lung disease;&#xD;
&#xD;
          3. DLCO≧40%;&#xD;
&#xD;
          4. Stable treatment for at least 12 weeks;&#xD;
&#xD;
          5. Patients with good compliance should sign informed consent before the tria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient is using or has used anti pulmonary fibrosis drugs;&#xD;
&#xD;
          2. Pulmonary infection, tumor and other connective tissue diseases;&#xD;
&#xD;
          3. Chronic obstructive pulmonary disease, bronchial asthma and tuberculosis;&#xD;
&#xD;
          4. Patients with severe hypertension, diabetes and heart, liver and renal failure;&#xD;
&#xD;
          5. Women with reproductive needs;&#xD;
&#xD;
          6. Idiopathic pulmonary interstitial disease;&#xD;
&#xD;
          7. The researcher thinks that it is not suitable to participate in this experiment;&#xD;
&#xD;
          8. Participants in other clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhujing Zhu, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Longhua Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianchun Mao, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Longhua Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huanru Qu, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Longhua Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhujing Zhu, Ph.D</last_name>
    <phone>+8613816914874</phone>
    <email>zzj01@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianchun Mao, Master</last_name>
    <phone>+8618917763231</phone>
    <email>mjczyczx@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianchun Mao, master</last_name>
      <phone>86-18917763231</phone>
      <email>mjcct2018@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Primary Sjogren's syndrome</keyword>
  <keyword>Interstitial lung disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

